623 related articles for article (PubMed ID: 25374101)
1. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia.
Claxton A; Baker LD; Hanson A; Trittschuh EH; Cholerton B; Morgan A; Callaghan M; Arbuckle M; Behl C; Craft S
J Alzheimers Dis; 2015; 44(3):897-906. PubMed ID: 25374101
[TBL] [Abstract][Full Text] [Related]
2. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
[TBL] [Abstract][Full Text] [Related]
3. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.
Claxton A; Baker LD; Wilkinson CW; Trittschuh EH; Chapman D; Watson GS; Cholerton B; Plymate SR; Arbuckle M; Craft S
J Alzheimers Dis; 2013; 35(4):789-97. PubMed ID: 23507773
[TBL] [Abstract][Full Text] [Related]
4. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Craft S; Baker LD; Montine TJ; Minoshima S; Watson GS; Claxton A; Arbuckle M; Callaghan M; Tsai E; Plymate SR; Green PS; Leverenz J; Cross D; Gerton B
Arch Neurol; 2012 Jan; 69(1):29-38. PubMed ID: 21911655
[TBL] [Abstract][Full Text] [Related]
5. A Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Therapeutic Efficacy of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease.
Rosenbloom M; Barclay TR; Kashyap B; Hage L; O'Keefe LR; Svitak A; Pyle M; Frey W; Hanson LR
Drugs Aging; 2021 May; 38(5):407-415. PubMed ID: 33719017
[TBL] [Abstract][Full Text] [Related]
6. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial.
Craft S; Raman R; Chow TW; Rafii MS; Sun CK; Rissman RA; Donohue MC; Brewer JB; Jenkins C; Harless K; Gessert D; Aisen PS
JAMA Neurol; 2020 Sep; 77(9):1099-1109. PubMed ID: 32568367
[TBL] [Abstract][Full Text] [Related]
7. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
Reger MA; Watson GS; Green PS; Baker LD; Cholerton B; Fishel MA; Plymate SR; Cherrier MM; Schellenberg GD; Frey WH; Craft S
J Alzheimers Dis; 2008 Apr; 13(3):323-31. PubMed ID: 18430999
[TBL] [Abstract][Full Text] [Related]
8. Association between white matter hyperintensity severity and cognitive impairment according to the presence of the apolipoprotein E (APOE) ε4 allele in the elderly: retrospective analysis of data from the CREDOS study.
Son SJ; Lee KS; Lee Y; Baek JH; Choi SH; Na DL; Seo SW; Oh BH; Hong CH
J Clin Psychiatry; 2012 Dec; 73(12):1555-62. PubMed ID: 23146133
[TBL] [Abstract][Full Text] [Related]
9. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease.
Kellar D; Lockhart SN; Aisen P; Raman R; Rissman RA; Brewer J; Craft S
J Prev Alzheimers Dis; 2021; 8(3):240-248. PubMed ID: 34101779
[TBL] [Abstract][Full Text] [Related]
10. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype.
Reger MA; Watson GS; Frey WH; Baker LD; Cholerton B; Keeling ML; Belongia DA; Fishel MA; Plymate SR; Schellenberg GD; Cherrier MM; Craft S
Neurobiol Aging; 2006 Mar; 27(3):451-8. PubMed ID: 15964100
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease.
Stein MS; Scherer SC; Ladd KS; Harrison LC
J Alzheimers Dis; 2011; 26(3):477-84. PubMed ID: 21694461
[TBL] [Abstract][Full Text] [Related]
12. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease.
Rosenbloom MH; Barclay TR; Pyle M; Owens BL; Cagan AB; Anderson CP; Frey WH; Hanson LR
CNS Drugs; 2014 Dec; 28(12):1185-9. PubMed ID: 25373630
[TBL] [Abstract][Full Text] [Related]
13. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease.
Kennedy RE; Cutter GR; Schneider LS
Alzheimers Dement; 2014 May; 10(3):349-59. PubMed ID: 23712001
[TBL] [Abstract][Full Text] [Related]
14. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
[TBL] [Abstract][Full Text] [Related]
15. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
16. Intranasal insulin improves cognition and modulates beta-amyloid in early AD.
Reger MA; Watson GS; Green PS; Wilkinson CW; Baker LD; Cholerton B; Fishel MA; Plymate SR; Breitner JC; DeGroodt W; Mehta P; Craft S
Neurology; 2008 Feb; 70(6):440-8. PubMed ID: 17942819
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein epsilon4 and neuropsychological performance in Alzheimer's disease and vascular dementia.
McGuinness B; Carson R; Barrett SL; Craig D; Passmore AP
Neurosci Lett; 2010 Oct; 483(1):62-6. PubMed ID: 20678545
[TBL] [Abstract][Full Text] [Related]
18. Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.
Foster JK; Albrecht MA; Savage G; Lautenschlager NT; Ellis KA; Maruff P; Szoeke C; Taddei K; Martins R; Masters CL; Ames D;
Brain; 2013 Jul; 136(Pt 7):2201-16. PubMed ID: 23737466
[TBL] [Abstract][Full Text] [Related]
19. The APOE ε4 allele is associated with increased frontally mediated neurobehavioral symptoms in amnestic MCI.
Mikos AE; Piryatinsky I; Tremont G; Malloy PF
Alzheimer Dis Assoc Disord; 2013; 27(2):109-15. PubMed ID: 22874659
[TBL] [Abstract][Full Text] [Related]
20. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
